Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9466605 | 0.81 | KDM4E (0.37) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL9275470 | 0.74 | USP2 (0.32) | KDM4EPARP1ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL9059979 | 0.73 | CYP3A4 (0.40) | KDM4EPARP1ALDH1A1HPGDUSP2 | |
| SCHEMBL6940291 | 0.71 | PNP (0.35) | KDM4EALDH1A1HPGDUSP2MEN1 | |
| SCHEMBL7663881 | 0.70 | KDM4E (0.58) | KDM4EALDH1A1HPGDUSP2MEN1 | |
| SCHEMBL20866 | 0.70 | ATAD2 (0.41) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL27398200 | 0.67 | KDM4E (0.42) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL18954300 | 0.67 | KDM4E (0.51) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL12900061 | 0.67 | KDM4E (0.42) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL14337027 | 0.66 | PARP1 (0.50) | KDM4EPARP1ALDH1A1L3MBTL1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 672 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| US-10968248-B2 | Trinucleotide mRNA cap analogs | Arcturus, Inc. (US) | 2021-04-06 | — | — | US | claimed |
| US-20200040026-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | ARCTURUS THERAPEUTICS, INC. | 2020-02-06 | — | — | US | claimed |
| EP-2179039-B1 | RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES | ZOETIS BELGIUM S A (BE) | 2018-10-31 | — | — | EP | claimed |
| US-9284343-B2 | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-15 | — | — | US | claimed |
| EP-2451475-A2 | SELF REPLICATING RNA MOLECULES AND USES THEREOF | Novartis AG (CH) | 2012-05-16 | — | — | EP | claimed |
| US-20110300205-A1 | SELF REPLICATING RNA MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2011-12-08 | — | — | US | claimed |
| WO-2011005799-A2 | SELF REPLICATING RNA MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2011-01-13 | — | — | WO | claimed |
| CN-101821392-A | RNA sequence motifs inducing specific immunomodulatory properties in a defined internucleotide linkage environment | COLEY PHARM GMBH | 2010-09-01 | — | — | CN | claimed |
| WO-2009022216-A2 | RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES | COLEY PHARMACEUTICAL GMBH (US) | 2009-02-19 | — | — | WO | claimed |
| WO-2008033432-A2 | IMMUNE MODULATION BY CHEMICALLY MODIFIED RIBONUCLEOSIDES AND OLIGORIBONUCLEOTIDES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-1899467-A2 | MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCES IMMUNOSTIMULATORY ACTIVITY | Coley Pharmaceutical GmbH (DE) | 2008-03-19 | — | — | EP | claimed |
| CN-1973821-A | Medicine composition containing both anticancer medicine and its synergist | SHANDONG LANJIN BIOENGINEERING (CN) | 2007-06-06 | — | — | CN | claimed |
| WO-2006116458-A2 | MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCES IMMUNOSTIMULATORY ACTIVITY | COLEY PHARMACEUTICAL GMBH (DE) | 2006-11-02 | — | — | WO | claimed |
| US-20060241076-A1 | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity | COLEY PHARMACEUTICAL GMBH (DE) | 2006-10-26 | — | — | US | claimed |
| US-20050239727-A1 | for use in cosmetics, drugs | SILDEHA SWISS SA (CH) | 2005-10-27 | — | — | US | claimed |
| EP-1525224-A1 | HYALURONIC ACID DERIVATIVES | Jasper Ltd. Liability Co. (US) | 2005-04-27 | — | — | EP | claimed |
| EP-1518854-A1 | Substituted 06- benzylguanines and 7- or 9- substituted 8-aza-06-benzylguanines | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2005-03-30 | — | — | EP | claimed |
| WO-2004013182-A1 | HYALURONIC ACID DERIVATIVES | JASPER LTD LIABILITY CO. (US) | 2004-02-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239727-A1 | for use in cosmetics, drugs | HINT1, NUDT1, NNT | KDM4E 3870/4885PARP1 215/4885ALDH1A1 175/4885 |
| US-20200040026-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | RNGTT, RNMT, NSUN2 | KDM4E 2423/4885PARP1 668/4885ALDH1A1 4732/4885 |
| US-10968248-B2 | Trinucleotide mRNA cap analogs | RNGTT, RNMT, NSUN2 | KDM4E 2423/4885PARP1 668/4885ALDH1A1 4732/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | KDM4E 124/4885PARP1 3044/4885ALDH1A1 822/4885 |
| US-20060241076-A1 | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity | TLR3, TLR8, TLR9 | KDM4E 1276/4885PARP1 245/4885ALDH1A1 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.